behind the development of an innovative fuel additive-Nuel

about Dr. Stella Gengrinovitch

Dr. Stella Gengrinovitch co-founded BioSight Pharma in 2000, a pioneering pharmaceutical company specializing in cancer therapies, with a focus on developing innovative treatments for leukemia. Over her 18-year tenure at BioSight, she served as Chief Scientific Officer (CSO) and Vice President of Research and Development, where she spearheaded the development of groundbreaking drugs and therapeutic formulations. Her flagship drug, Aspacytarabine, is currently undergoing advanced clinical trials worldwide. BioSight’s success culminated in its acquisition through a strategic merger and acquisition (M&A) with a leading American pharmaceutical company.

In 2014, Dr. Gengrinovitch co-founded Keepers of the Void, a company dedicated to creating cutting-edge technologies, products, and software for academic and industrial applications. She has provided consultancy to a wide range of companies and projects in the biomedicine and medical device sectors, contributing her expertise in the design and synthesis of diagnostic and therapeutic peptides. Her collaborations include renowned organizations such as:

  • Bioline RX (cancer therapeutics)
  • Tagra (microencapsulation technologies for cosmetics)
  • Savion Diagnostics (diagnostic kits)
  • Stentonics (drug-eluting stents)
  • PressQ (intuitive allergy injectors)
partnered with academic institutions

Additionally, she has partnered with academic institutions, including Prof. Miri Blank’s lab at the Sheba Medical Center (immune peptides), Prof. Smadar Cohen at Ben-Gurion University (therapeutic peptides), and Prof. Asher Schmidt at the Technion (calcium crystallization and stabilization).

With extensive experience in managing R&D-driven startups, Dr. Gengrinovitch brings unparalleled expertise in biochemistry, drug development, material science, and medical device innovation. Her multidisciplinary skills are reflected in numerous patents and publications associated with the Technion, BioSight, and other ventures.

Dr. Stella Gengrinovitch holds a B.Sc., M.Sc., and Ph.D. in Biochemistry from the prestigious Technion – Israel Institute of Technology in Haifa, Israel. Notably, patents generated from her doctoral and postdoctoral research were instrumental in the development of innovative drugs later licensed to Gilead Sciences, solidifying her legacy as a leader in pharmaceutical innovation